INDV Indivior
- 15.860
- -0.480-2.94%
- 16.430
- +0.570+3.59%
Indivior News
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $Indivior(INDV.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 0.0% and a total average return of 0.0% over the
Indivior Doses First Subject In Phase 2 Study Of INDV-2000 For Opioid Use Disorder, Assessing Safety And Efficacy Over 3 Months In Treatment-Seeking Individuals
Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder.INDV-2000 is an investigational non-op
Opioid Use Disorder in the 7MM: Epidemiology Insights and Forecast 2024-2034 Featuring Detailed Analysis of Marketed and Late-Stage Pipeline Drugs, Including Subutex and INDV-2000 (Indivior)
Indivior PLC Shares Update and Voting Rights
Indivior PLC Announces Share Buyback and Cancellation
Indivior PLC Executes Share Buyback Program
With 59% Ownership, Indivior PLC (LON:INDV) Boasts of Strong Institutional Backing
Stifel Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $33.9
Stifel analyst Max Herrmann maintains $Indivior(INDV.US)$ with a buy rating, and maintains the target price at $33.9.According to TipRanks data, the analyst has a success rate of 53.0% and a total ave
Indivior PLC Embraces Nasdaq Move With Shareholder Approval
Indivior Shareholders Approve Main Listing Switch to U.S.
By Ian Walker Indivior shareholders have approved the company's plan to switch its main listing to the U.S. dealing a further blow to the London Exchange after a string of recent defections. The pha
Indivior: Resolution Set Out in Notice of Meeting Was Duly Passed by Shareholders
Indivior: Resolution Set Out in Notice of Meeting Was Duly Passed by Shareholders
Indivior Outlines Growth and Confirms 2024 Guidance
Indivior Provided Guidance Ahead of Analyst Teach-in Event in NY City
Indivior Provided Guidance Ahead of Analyst Teach-in Event in NY City
Indivior Sees Adjusted Operating Profit of $330m-$380m
Indivior Sees Adjusted Operating Profit of $330m-$380m
Indivior Sees Adjusted Gross Margin Low to Mid-80s Range
Indivior Sees Adjusted Gross Margin Low to Mid-80s Range
Indivior PLC Sees 2024 Sublocade Net Revenue of $820m-$880m
Indivior PLC Sees 2024 Sublocade Net Revenue of $820m-$880m
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the...
Indivior PLC Sees 2024 Rev $1.24B-$1.33B
Indivior PLC Sees 2024 Rev $1.24B-$1.33B
Indivior PLC Backs View
Indivior PLC Backs View
Indivior PLC Completes Share Buyback and Cancellation
Analysis
Price Target
No Data
